663 related articles for article (PubMed ID: 30861110)
1. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
2. Patients' preference for migraine preventive therapy.
Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
[TBL] [Abstract][Full Text] [Related]
3. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
4. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
[TBL] [Abstract][Full Text] [Related]
5. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
6. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.
Matza LS; Deger KA; Vo P; Maniyar F; Goadsby PJ
Qual Life Res; 2019 Sep; 28(9):2359-2372. PubMed ID: 30924071
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
[TBL] [Abstract][Full Text] [Related]
8. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.
Lloyd A; McIntosh E; Price M
Pharmacoeconomics; 2005; 23(11):1167-81. PubMed ID: 16277551
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
[TBL] [Abstract][Full Text] [Related]
10. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
[TBL] [Abstract][Full Text] [Related]
11. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
[TBL] [Abstract][Full Text] [Related]
12. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.
Mohamed AF; Kilambi V; Luo MP; Iyer RG; Li-McLeod JM
J Med Econ; 2012; 15(6):1183-91. PubMed ID: 22846048
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
14. Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment.
Hiligsmann M; Dellaert BG; Dirksen CD; van der Weijden T; Goemaere S; Reginster JY; Watson V; Boonen A
Arthritis Res Ther; 2014 Jan; 16(1):R36. PubMed ID: 24479410
[TBL] [Abstract][Full Text] [Related]
15. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
16. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment.
Gonzalez JM; Johnson FR; Runken MC; Poulos CM
Headache; 2013; 53(10):1635-50. PubMed ID: 23808578
[TBL] [Abstract][Full Text] [Related]
17. Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment.
Si L; Tu L; Xie Y; Palmer AJ; Gu Y; Zheng X; Li J; Lv Q; Qi J; Lin Z; Chen M; Gu J; Hiligsmann M
Arch Osteoporos; 2019 Jul; 14(1):85. PubMed ID: 31367860
[TBL] [Abstract][Full Text] [Related]
18. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
[TBL] [Abstract][Full Text] [Related]
19. Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment.
Morse AM; Krahn L; Flygare J; Kushida C; Thorpy MJ; Athavale A; Gudeman J
Adv Ther; 2023 Jul; 40(7):3199-3216. PubMed ID: 37243863
[TBL] [Abstract][Full Text] [Related]
20. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
